FEB 1 3 2000 FEB 1 2000 FE

AF/1644

Patent

Attorney's Docket No. 002010-742

THE UNITED STATES PATENT AND TRADEMARK OFFICE

P#23

In re Patent Application of

Mary M. BENDIG et al.

Application No.: 09/155,739

Filed: September 11, 1998

For:

THERAPEUTIC USES OF

HUMANIZED ANTIBODIES AGAINST

ALPHA-4 INTEGRIN

BOX AF

Group Art Unit: 1644

Examiner: Phillip Gambel

Confirmation No.: 9068

RECEIVED

FEB 2 0 2003

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- [] No additional fee for submission of an IDS is required.
- The fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- [] A statement under 37 C.F.R. § 1.97(e) is also enclosed.
- [X] A statement under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- [] Charge \$_____ to Deposit Account No. 02-4800 for the fee due.
- [X] A check in the amount of \$_180.00_\ is enclosed for the fee due.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

gistration No

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

Date: February 13, 2003

02/14/2003 MGEBREM1 00000051 09155739

01 FC:1806

180.00 GP

Attorney's Docket No. 002010-742

FEB 1 3 2003 E

THE UNITED STATES PATENT AND TRADEMARK OFFICE

| In re Patent Application of |) BOX AF | |
|--|----------------------------|---------------------|
| Mary M. BENDIG et al. |) Group Art Unit: 1644 | |
| Application No.: 09/155,739 |) Examiner: Phillip Gambel | |
| Filed: September 11, 1998 |) Confirmation No.: 9068 | RECEIVED |
| For: THERAPEUTIC USES OF HUMANIZED ANTIBODIES AGAINST ALPHA-4 INTEGRIN |))) | FEB 2 0 2003 |

INFORMATION DISCLOSURE STATEMENT

TECH CENTER 1600/2900

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

Consideration and making of record in the application identified in caption of the accompanying Information Disclosure Statement are respectfully requested. A statement in accordance with 37 C.F.R. § 1.97(e) and an IDS fee set forth in 37 C.F.R. § 1.17(p) in the amount of \$180.00 (1806) are being submitted to comply with the provisions of 37 C.F.R. § 1.97(d).

- I, the undersigned, hereby state that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office dated January 23, 2003 in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
- I, the undersigned, hereby state that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office dated January 23, 2003 in a counterpart application and that this communication was not received by any individual designated in § 1.56(c) more than 30 (thirty) days prior to the filing of this Information Disclosure Statement.

Information Disclosure Statement Application No. <u>09/155,739</u> Attorney's Docket No. 002010-742 Page 2

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner-initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date: February 13, 2003

P.O. Box 1404 Alexandria, Virginia 22313-1404

(703) 836-6620

| SHEET LOD | | SH | EE. | T 1 | OF | 1 |
|-----------|--|----|-----|-----|----|---|
|-----------|--|----|-----|-----|----|---|

FEB 1 3 2003 B NFORMATION DISCLOSURE STATEMENT BY APPLICANT

| ATTORNEY'S DKT No. 002010-742 | APPLICATION No. 09/155,739 |
|---------------------------------|----------------------------|
| APPLICANT Mary M. BENDIG et al. | |
| FILING DATE | GROUP |
| September 11, 1998 | 1644 |

| U.S. PATENT DOCUMENTS | | | | | | | |
|--|---|--|--|-------------------------------|--|--------------|---------------|
| Examiner Initials | Document Number | Kind Code (if known) | Name of Patentee or Applicant Date | | sue/Publication Date MM-DD-YYYY) | | |
| | - | | | RECEIVI | ED | | |
| ļ | | | | ILOLI V | | | |
| | | | | FEB 2 0 201 | 13 | | |
| | | | | | | | |
| | | | TECH CENTER 1600/2900 | | | | |
| | | <u> </u> | | | | | |
| | | FO | REIGN PATENT DOCUMENTS | | | | |
| Examiner Initials | Document Number | Kind Code (if known) | Country | Date of Publica (MM-DD-YYY | | Trans Yes | slation No |
| madio | WO 96/01644 | A1 | PCT | 01-25-199 | | 100 | |
| | WO 95/19790 | A1 | PCT | 07-27-199 | 5 | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | ļ |
| | | | | | | | ļ |
| | | | | 1 | | | |
| | - to about | | ATENT LITERATURE DOCUMENTS | | -541 | | |
| Examiner Initials | item (bool | k, magazine, jour | r (in CAPITAL LETTERS), title of the article (whe rnal, serial, symposium, catalog, etc.), date, page publisher, city and/or country where published. | (s), volume-issue r | | (s), | |
| | | | oort mailed January 23, 2003 e Adhesion to Endothelium in Simian Immunode | ficiency Virus-Indu | OIA hor | 15 | |
| | Encephalitis is Media | ated by Vascular ol. 144, No. 1, Am | Cell Adhesion Molecule-1/α4β1 Integrin Interaction perican Society for Investigative Pathology with the | ons", American Jou | ırnal of | Patholo | |
| | and Cellular Infiltration | on in the Guinea | to Very Late Activation Antigen 4 Prevents Antig Pig Airways", J. Exp. Med., 1994, pgs. 795-805, \ of Stanford University Libraries' HighWire Press, \(\) | Vol. 180, No. 3, The | e Rock | | ivity |
| | Vivo", J. Exp. Med., | 1993, pgs. 561-5 | ody Recognizing Very Late Activation Antigen-4 66, Vol. 177, No. 2, The Rockefeller University Po Stanford, California, USA | | | | |
| L.C. PAUL et al., "Monoclonal Antibodies Against LFA-1 and VLA-4 Inhibit Graft Vasculitis in Rat Cardiac Allografts", Transplantation Proceedings, 1993, pgs. 813-814, Vol. 25, No. 1, Pt. 1, Elsevier Science, Oxford, United Kingdom | | | | | | | |
| | Patricia L. CHISHOLM <i>et al.</i> , "Monoclonal Antibodies to the Integrin α-4 Subunit Inhibit the Murine Contact Hypersensitivity Response", Eur. J. Immunol., 1993, pgs. 682-688, Vol. 23, No. 3, VCH Verlagsgesellschaft mbH, Weinheim, Germany | | | | | | |
| | Clin. Invest., 1993, p | gs. 372-380, Vol. | tion of Colitis in the Cotton-Top Tamarin by Anti- 92, No. 1, The American Society for Clinical Invi e Press, Stanford, California, USA | | | | |
| | Antigen-4 Abrogates No. 2, Academic Pre | Predisposing Au ss, Inc., Elsevier | stration of Monoclonal Antibodies Against Vascul toimmune Diabetes in NOD Mice", Cellular Immu Science, Oxford, United Kingdom | ınology, 1995, pgs. | 193-20 | 01, Vol. | . 165, |
| | Science, 1991, pgs. | 788-791, Vol. 25 [.] | ial Expression of a Mononuclear Leukocyte Adhe 1, No. 4995, American Association for the Advand Vire Press, Stanford, California, USA | | | | |

| Examiner | Date | |
|-----------|------------|--|
| Signature | Considered | |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.